The findings are based on research on hospitalised babies in NSW over a 10 year period.
They point to the importance of active immunisation in a child’s first two years to reduce the onset of asthma. This would augment maternal vaccination against respiratory syncytial viral (RSV) disease.
RSV is the leading cause of lower respiratory tract infections like bronchiolitis in infants and, in severe cases, requires hospitalisation.
Early RSV disease is also a strong predictor of childhood asthma.
Lead researcher Dr Nusrat Homaira from UNSW’s School of Women's and Children's Health says the research has important implications for the development and implementation of a promising vaccine which is now in its third and final stage of testing.
“In the last 10 years there has been unprecedented development of a vaccine for RSV because it's such a huge problem,” said Dr Homaira. Eighty percent of infants get the disease by their second birthday.
“The vaccine under development is going to be given to women during their third trimester to boost the maternal antibodies, which will protect babies against severe RSV.”
However, Dr Homaira says protection from a ‘passive’ vaccine administered to an expectant mother may only protect as far as six months into the baby’s life following birth. After this time, an infant could still develop an RSV infection.
This is where the new research provides some new knowledge. Dr Homaira and her co-authors looked at 18,042 children with severe RSV disease who were hospitalised in their first two years of life in NSW between 2001 and 2010 and saw two interesting patterns emerge.
First, 60% of all admissions were for infants aged six months or younger.
“This confirmed that there is a very good reason to develop the maternal vaccine, because it is going to protect them in the first six months of their life,” said Dr Homaira.
But it was the second finding that surprised the team – of the 40% of infants who were hospitalised after the age of six months, more went on to return to hospital with severe asthma in later years than those who contracted RSV in their first six months of life.
“So what our analysis showed is that even though you get more RSV in the first six months of life, if you get severe RSV after six months of age, the rate of subsequent asthma is actually higher in those children.”
The authors believe this new knowledge should inform the strategy to implement the immunisation against RSV once the trial phase has ended to boost immunity beyond the reach of the maternal vaccine.
“While the maternal vaccine is extremely important for our children, we also need an active vaccination strategy or an active vaccine candidate that is going to protect children in the first two years of life,” Dr Homaira says.
Dr Homaira is part of a worldwide study into RSV which aims to look into the burden of RSV disease and provide data necessary for vaccine development. She says she is very optimistic about the maternal vaccine and hopes it will be available in about two years.
The study was published in December in the Journal of Infectious Diseases.